Inactive Instrument

News BioPlus Acquisition Corp. Nasdaq

Equities

BIOSU

KYG112171098

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

BioPlus Acquisition Corp.(NasdaqGM:BIOS) dropped from NASDAQ Composite Index	10/10/23	CI
BioPlus Acquisition, Avertix Medical Terminate Business Combination Deal	04/10/23	MT
BioPlus Acquisition Corp. Announces Termination of Business Combination Agreement with Avertix Medical, Inc. and its Intention to Liquidate	04/10/23	AQ
Avertix Medical, Inc. terminated the acquisition of BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others in a reverse merger transaction.	03/10/23	CI
Heart & Rhythm Institute of Trinity and Avertix Announce Partnership to Improve Cardiac Care and Patient Monitoring	16/08/23	AQ
BioPlus Acquisition Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Renown Cardiologist and Professor Ian T. Meredith, MD to Join Avertix Medical’s Board of Directors	17/07/23	AQ
Avertix’s Guardian™ System, First and Only FDA-Approved Implantable Heart Attack Detection and Warning System, Now Available at AdventHealth Orlando	13/06/23	AQ
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	08/06/23	AQ
BioPlus Acquisition Corp. announced that it has received $1.5 million in funding	01/06/23	CI
BIOPLUS ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	30/05/23	AQ
BioPlus Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
BIOPLUS ACQUISITION CORP. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	03/05/23	AQ
Avertix Medical, Inc. entered into a definitive merger agreement to acquire BioPlus Acquisition Corp. from BioPlus Sponsor LLC, Highbridge Capital Management, LLC, Saba Capital Management, L.P., Cantor Fitzgerald & Co, Investment Arm and others for approximately $170 million in a reverse merger transaction.	02/05/23	CI
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	31/03/23	AQ
BioPlus Acquisition Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	31/03/23	CI
BioPlus Acquisition Corp. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
BIOPLUS ACQUISITION CORP. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	03/11/22	AQ
BioPlus Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	03/11/22	CI
BIOPLUS ACQUISITION CORP. : Other Events (form 8-K)	11/10/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News BioPlus Acquisition Corp. Nasdaq

Equities

BIOSU

KYG112171098

Summary

Filters